Compares JNJ-79635322 with teclistamab in adults with relapsed or hard-to-treat multiple myeloma
Compares JNJ-79635322 with another antibody therapy in adults with relapsed multiple myeloma.
Plain-language title generated from the registry record
Registry title: A Study Comparing JNJ-79635322 and an Anti-B-cell Maturation Antigen (BCMA)xCD3 Bispecific Antibody in Participants With Relapsed or Refractory Multiple Myeloma
Key facts
- Where
- Calgary, Halifax, Hamilton, London, Montreal, Toronto, and Vancouver, CanadaSee the 7 sites
- Phase
- Phase 3
AI summary: who the study is looking for
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with multiple myeloma that came back or stopped responding after at least 3 earlier lines of treatment. It compares JNJ-79635322 with teclistamab.
- Age
- 18 years or older
- Sex
- Men and women can join
- Disease stage
- Multiple myeloma with measurable disease at screening. The disease has grown or has not responded to the last line of treatment.
- Earlier treatment
- At least 3 earlier lines of myeloma treatment, including a proteasome inhibitor (PI), an immunomodulatory drug (IMiD) and an anti-CD38 antibody. Side effects from earlier cancer treatment must have settled to Grade 1 or better.
Main reasons for not taking part
- Active hepatitis caused by an infection
- Current or past myeloma in the brain or spinal cord area (central nervous system), or signs of meningeal involvement
- Known or suspected allergy to the ingredients of JNJ-79635322 or teclistamab
- Major surgery within 2 weeks before the first dose, or not yet recovered, or surgery planned during the trial
- Live, weakened vaccine within 4 weeks before the first dose or during treatment
Read by machine on 9 November 2026.
Where in Canada
- Arthur J.E. Child Comprehensive Cancer CentreCalgary, CanadaTaking people
- Queen Elizabeth II, Health Sciences CentreHalifax, CanadaTaking people
- Juravinski Cancer CentreHamilton, CanadaTaking people
- London Health Sciences CentreLondon, CanadaTaking people
- CIUSSS de l Est de l Ile de Montreal Installation Hopital Maisonneuve RosemontMontreal, CanadaTaking people
- University Health Network UHN Princess Margaret Cancer CentreToronto, CanadaTaking people
- British Columbia Cancer AgencyVancouver, CanadaTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorTrial details
- Who runs it
- Janssen Research & Development, LLC
- Trial code
- NCT07258511EU 2025-522007-18-00
- Record updated
- 3 November 2026
- Original description
The purpose of this study is to evaluate how well JNJ-79635322 works when compared with an anti-B-cell maturation antigen (BCMA)xCD3 bispecific antibody.Read full original descriptionShow less
A Phase 3 Randomized Study Comparing JNJ-79635322 and an Anti-BCMAxCD3 Bispecific Antibody in Participants With Relapsed or Refractory Multiple Myeloma Who Have Received at Least 3 Prior Lines of Therapy Including a PI, an IMiD, and an Anti CD38 Antibody
The purpose of this study is to evaluate how well JNJ-79635322 works when compared with an anti-B-cell maturation antigen (BCMA)xCD3 bispecific antibody.
Inclusion:; Documented diagnosis of multiple myeloma (MM) as defined by the criteria below:; MM diagnosis according to the international myeloma working group (IMWG) diagnostic criteria; Measurable disease at screening as assessed by central laboratory; Received at least 3 prior lines of antimyeloma therapy including a proteasome inhibitor (PI), an immunomodulatory drug (IMiD), and an anti-cluster of differentiation (CD)38 antibody; Documented evidence of progressive disease (PD) or failure to achieve a response to the last line of therapy based on investigator's determination of response by IMWG criteria; Toxicity related to previous anticancer therapy must have resolved to Grade 1 or better; Have an eastern cooperative oncology group (ECOG) performance status of 0 to 2 at screening and immediately before the start of study treatment administration; Exclusion:; Active hepatitis of infectious origin; Known active or prior central nervous system (CNS) involvement or exhibits clinical signs of meningeal involvement of MM; Suspected or known allergies, hypersensitivity, or intolerance to the excipients of JNJ-79635322 and Teclistamab; Major surgery, (example, requiring general anesthesia) within 2 weeks before first dose, or will not have fully recovered from surgery, or has surgery planned during the time the participant is expected to participate in the study; Received or plans to receive any live, attenuated vaccine within 4 weeks before the first dose of study treatment, or during study treatment.